Preferential Treatment: US FDA Asks Patients For Their Input

03 May 2019

As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.

Shuren_Jeff_1200 — Michael McCaughan (left) speaking with CDRH Director Jeff Shuren at the Reagan-Udall Foundation for FDA on 2 May. • Source: Ferdous Al-Faruque

The US Food and Drug Administration wants public input that could allow patients to have more influence over the kinds of products they want to have access to.

While the agency has the final say on what devices get to market, regulators have been tasked with figuring out...